VISCHER advised Synendos in closing CHF 20 million Series A financing round

Synendos Therapeutics, a biopharmaceutical company developing a new class of small molecules designed to restore the natural function of the endocannabinoid system in the brain and have the potential to treat a variety of central nervous system (CNS) disorders , closed its Series A financing round of CHF 20 million. 

The financing was carried out under the joint management of Kurma Partners and Sunstone Life Science Ventures with the participation of BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors. Synendos will primarily use the funds raised to

The team 

VISCHER advised Synendos on all legal issues in connection with the transaction. The team included Christian Wyss (Partner, Corporate / M&A – pictured), Luzius Zumstein (Senior Associate, Corporate / M&A) and Dario Glauser (Trainee, Corporate / M&A).